Cephalon Defends Narcolepsy Drug From Generics At Trial

Law360, Wilmington (July 18, 2012, 8:51 PM EDT) -- Cephalon Inc. squared off with a host of generic-drug makers in Delaware federal court on Wednesday in a patent infringement suit aiming to block generic versions of its narcolepsy drug Nuvigil from hitting the market.

On the second day of trial in the case, defense experts took the stand to bolster the case of Mylan Pharmaceuticals Inc. and other generics makers that their products are based on a long-expired Cephalon patent that anticipates the current Nuvigil patent and renders it invalid. In the alternative, the defendants...
To view the full article, register now.